Table 2

Exposure-adjusted incidence rates of adverse events of special interest in the 2 mg and 4 mg subsets of the All-bari-RA analysis set

Ever on 2 mg (N=1077) (PYE=2678)
EAIR (95% CI)		Ever on 4 mg (N=3401) (PYE=11 872)
EAIR (95% CI)		All-bari-RA (N=3770) (PYE=14 744)
IR (95% CI)
Death0.56 (0.31 to 0.92)0.57 (0.44 to 0.73)0.56 (0.45 to 0.70)
Serious infections2.13 (1.61 to 2.76)2.62 (2.34 to 2.93)2.58 (2.33 to 2.86)
Thromboembolic events
 DVT/PE0.49 (0.26 to 0.83)0.51 (0.39 to 0.66)0.49 (0.38 to 0.61)
 DVT0.41 (0.21 to 0.73)0.35 (0.25 to 0.48)0.35 (0.26 to 0.45)
 PE0.26 (0.11 to 0.54)0.27 (0.18 to 0.38)0.26 (0.18 to 0.35)
MACE*0.42 (0.21 to 0.74)0.54 (0.41 to 0.69)0.51 (0.40 to 0.64)

  • *Positively adjudicated events of myocardial infarction, stroke and cardiovascular deaths.

  • bari, baricitinib; DVT, deep vein thrombosis; EAIR, exposure-adjusted incidence rate; IR, incidence rate; MACE, major adverse cardiovascular events; N, number of patients in the analysis set; PE, pulmonary embolism; PYE, patient-years of exposure; RA, rheumatoid arthritis.